Plasminogen activator inhibitor-1 (PAI-1) : pathogenetic role in coronary disease
Młynarska, A.; Waszyrowski, T.; Kasprzak, J.ła.D.
Kardiologia Polska 65(9): 1109-1114
2007
ISSN/ISBN: 0022-9032 PMID: 17975760 Document Number: 606683
Document emailed within 1 workday
Related Documents
Glas-Greenwalt, P.; Hall, J.M.; Panke, T.W.; Kant, K.S.; Allen, C.M.; Pollak, V.E. 1986: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura Journal of Laboratory and Clinical Medicine 108(5): 415-422Nordt, T.K.; Peter, K.; Ruef, J.; Kübler, W.; Bode, C. 1999: Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease Thrombosis and Haemostasis 82(Suppl 1): 14-18
Kruithof, E.K.; Gudinchet, A.; Bachmann, F. 1988: Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states Thrombosis and Haemostasis 59(1): 7-12
Chen, Z.Y. 1993: A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease Zhonghua Xin Xue Guan Bing Za Zhi 21(3): 163-164; 188
Sprengers, E.D.; Akkerman, J.W.; Jansen, B.G. 1986: Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood Thrombosis and Haemostasis 55(3): 325-329
Habib, S.S.; Abdel Gader, A.G.M.; Kurdi, M.I.; Suriya, M.O.; Al Aseri, Z. 2012: Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina JPMA. Journal of the Pakistan Medical Association 62(7): 681-685
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576
Yamada, R.; Yamada, S.; Ishii, A.; Tane, S. 1993: Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy Nippon Ganka Gakkai Zasshi 97(8): 955-960
De Moerloose, P.; Mermillod, N.; Amiral, J.; Reber, G. 1998: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1 Thrombosis and Haemostasis 79(3): 554-556
Fukao, H.; Yamamoto, K.; Matsuo, O. 1991: Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome Rinsho Byori. Japanese Journal of Clinical Pathology 39(7): 720-726
Shiba, E.; Kobayashi, T.; Yayoi, E.; Takatsuka, Y.; Koyama, H.; Takai, S.; Mori, T. 1992: Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report Nihon Geka Gakkai Zasshi 93(1): 109
Wallnöfer, A.E.; van Griensven, J.M.; Schoemaker, H.C.; Cohen, A.F.; Lambert, W.; Kluft, C.; Meijer, P.; Kooistra, T. 1993: Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans Thrombosis and Haemostasis 70(6): 1005-1008
Virji, M.A.; Aggarwal, S.; Kang, Y. 1989: Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation Transplantation Proceedings 21(3): 3540-3541
Kobayashi, Y.; Fukuo, Y.; Shibuya, T.; Terashi, A. 1990: The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 27(5): 578-583
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Hirschfield, G. 2001: Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal Thrombosis and Haemostasis 85(1): 189-190
Fujii, S.; Lucore, C.L.; Hopkins, W.E.; Billadello, J.J.; Sobel, B.E. 1990: Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells Thrombosis and Haemostasis 64(3): 412-419
Herszényi, L.; Plebani, M.; Cardin, R.; Carraro, P.; De Paoli, M.; Roveroni, G.; Naccarato, R.; Farinati, F. 1995: The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer Acta Physiologica Hungarica 83(3): 213-221
Rerolle, J.P.; Vigneau, C.; Hertig, A.; Berrou, J.; Rondeau, E. 2001: Plasminogen activator inhibitor type 1: physiology and role in renal physiopathology Nephrologie 22(1): 5-13
Jastrzebska, M.; Przybycień, K.; Chelstowski, K.; Torbus-Lisiecka, B.; Kornacewicz-Jach, Z.; Naruszewicz, M. 1999: Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography Nutrition Metabolism and Cardiovascular Diseases: Nmcd 9(1): 33-40